安全评价ivacaftor治疗囊肿性纤维化。
文章的细节
-
引用
复制到剪贴板 -
McColley SA
安全评价ivacaftor治疗囊肿性纤维化。
专家当今药物Saf。2016; 15(5): 709 - 15所示。doi: 10.1517 / 14740338.2016.1165666。Epub 2016年4月7日。
- PubMed ID
-
26968005 (在PubMed]
- 文摘
-
简介:Ivacaftor表示治疗囊肿性纤维化(CF)由10囊性纤维化跨膜电导调节突变的CFTR(检测)基因导致闸门或部分功能异常。在安慰剂对照和开放性研究,ivacaftor-treated主题显示改善肺功能,营养和生活质量的措施。本文综述ivacaftor安全。覆盖区域:安全在ivacaftor临床试验发现,和报道随后访问PubMed搜索使用关键字“vx - 770”或“ivacaftor”。必威国际app附加信息是通过谷歌搜索访问。必威国际appTransaminitis lumacaftor-ivacaftor在ivacaftor指出,组合试验。Ivacaftor与白内障在幼年鼠崽在临床前研究;非先天性白内障已发现在儿童ivacaftor。Ivacaftor CYP3A衬底;CYP3A抑制剂和诱发者应避免在其管理。 Ivacaftor and its M1 metabolite may inhibit CYP3A and P-gp; therefore, ivacaftor may increase systemic exposure to drugs which are substrates of CYP3A and/or P-gp, increasing the potential for adverse events. EXPERT OPINION: Ivacaftor therapy may be associated with ocular and hepatic side effects; specific recommendations for monitoring are available. Potential drug interactions should be evaluated in patients taking ivacaftor. High clinical efficacy suggests that the risk benefit ratio of ivacaftor favors therapy.